AXB 1701
Alternative Names: AXB-1701Latest Information Update: 04 Aug 2023
At a glance
- Originator Axceso Biopharma
- Class Anti-infectives; Phosphates
- Mechanism of Action SIRT1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Sepsis
Most Recent Events
- 10 Jul 2023 Early research in Sepsis in South Korea, prior to July 2023(Axceso biopharma pipeline, July 2023)
- 07 Feb 2023 Axceso Biopharma has patents protection for Use of P1P derivatives for the treatment of sepsis in Japan (Axceso biopharma website, July 2023)
- 16 Feb 2021 Axceso Biopharma has patents protection for Use of P1P derivatives for the treatment of sepsis in South Korea (Axceso biopharma website, July 2023)